Abstract:Background and Objectives Amyotrophic lateral sclerosis (ALS) is a rapidly progressing neurodegenerative disease with an increasing global burden. Available treatments for ALS present marginal efficacy. To identify novel candidate therapeutic targets for ALS, we conducted a proteome-wide Mendelian randomization (MR) study. Methods We leveraged data from the largest summary statistics for ALS to date (27,205 patients with ALS and 110,881 controls). Genetic instruments of more than 4,000 proteins defined by cis -protein quantitative loci (pQTL) genetic instruments on plasma and cerebrospinal fluid (CSF) were obtained from Fenland (discovery, n=10,709), deCODE (replication, n=35,559), and a recently published dataset (replication, n=971). To investigate the causal ALS-associated proteins, proteome-wide Mendelian randomization based on summary-data-based MR (SMR and multi-SNP-based SMR) were performed. Then, two-sample MR analyses using five additional methods were conducted as sensitivity analyses. To further address the linkage disequilibrium bias, heterogeneity in dependent instruments test and colocalization analyses were performed. Steiger filtering and bi-directional MR analyses were conducted to address the potential reverse causality. Four drug target datasets were searched to extract druggability profiles for candidate target proteins. In addition, we carried out a case-control study involving up to 21 patients with ALS and 21 matched controls to assess the protein levels difference in CSF for evidence triangulation. Results Genetically predicted levels of six circulating proteins were associated with incident ALS in primary SMR analysis. After removing proteins with any linkage disequilibrium bias , SHBG , SIGLEC7, and SIGLEC9 presented consistent associations with ALS risk, supported by medium-to-high colocalization across both plasma pQTL datasets. In CSF, higher level of SHBG was also causally associated with the risk of ALS. There was no reverse causality detected. The case-control study using CSF proteomics conducted in our center observed consistent alteration in the levels of SHBG and SIGLEC7 with MR prediction, further suggesting their functionally relevant to ALS as potential druggable targets. Discussion Combined with the findings from MR and our observational study, we prioritize SHBG , SIGLEC7, and SIGLEC9 as drug candidate proteins for ALS, and further studies are needed to verify our findings and elucidate the underlying mechanism. ### Competing Interest Statement The authors have declared no competing interest. ### Funding Statement This work was supported by the grant (81671245) to Zhi-Ying Wu from the National Natural Science Foundation of China and the Fundamental Research Funds for the Central Universities (2019XZZX001-01-04). ### Author Declarations I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained. Yes The details of the IRB/oversight body that provided approval or exemption for the research described are given below: Ethics Committee of the Second Affiliated Hospital gave ethical approval for this work. I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals. Yes I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance). Yes I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable. Yes Data used in Mendelian randomization study are available from referenced datasets listed in eTable 1 . Data from the proteomics study are available upon reasonable request. * ALS : Amyotrophic lateral sclerosis ATF6B : activating transcription factor 6 Beta CSF : cerebrospinal fluid CI : confidence interval CNS : central nervous system FDR : False discovery rate HEIDI : heterogeneity in dependent instruments HDGFRP3 : Hepatoma-derived growth factor-related protein IVW : inverse variance weighted GWAS : genome-wide association study LD : Linkage disequilibrium MR : Mendelian randomization NME4 : Nucleoside Diphosphate Kinase 4 pQTL : protein quantitative loci SHBG : sex hormone binding globulin SIGLEC7 : sialic acid binding lg like lectin 7 SIGLEC9 : sialic acid binding lg like lectin 9 SMR : summary data-based Mendelian randomization SOD1 : superoxide dismutase 1 SD : standard deviation TMT : Tandem Mass Tag TDP-43 : TAR DNA-binding protein 43 TPP1 : Tripeptidyl Peptidase 1

A Mendelian randomization study identifies proteins involved in neurodegenerative diseases

Proteomics analysis of plasma from middle-aged adults identifies protein markers of dementia risk in later life

Detection of biomarkers with a multiplex quantitative proteomic platform in cerebrospinal fluid of patients with neurodegenerative disorders.

Unraveling the role of plasma proteins in dementia: insights from two cohort studies in the UK, with causal evidence from Mendelian randomization

Two-sample Mendelian randomization analysis of 91 circulating inflammatory protein levels and amyotrophic lateral sclerosis

Identification of potential drug targets for amyotrophic lateral sclerosis by Mendelian randomization analysis based on brain and plasma proteomics

Integrating human brain proteomes with genome-wide association data implicates new proteins in Alzheimer’s disease pathogenesis

Causal association of circulating inflammatory proteins on neurodegenerative diseases: Insights from a mendelian randomization study

Large-Scale Mendelian Randomization Study Reveals Circulating Blood-based Proteomic Biomarkers for Psychopathology and Cognitive Task Performance

Causal relationship between immune cells and neurodegenerative diseases: a two-sample Mendelian randomisation study

Novel Plasma and Brain Proteins That Are Implicated in Multiple Sclerosis.

Causal association between plasma metabolites and neurodegenerative diseases

Deciphering causal protein biomarkers in Alzheimer's disease: Integrating a novel robust Mendelian randomization method for proteomics data analysis and AlphaFold3 for predicting 3D structural alterations

Proteogenomic analysis of human cerebrospinal fluid identifies neurologically relevant regulation and implicates causal proteins for Alzheimer's disease

Large-scale proteomic analyses of incident Alzheimer's disease reveal new pathophysiological insights and potential therapeutic targets

Prioritization of Therapeutic Targets for Amyotrophic Lateral Sclerosis Using Protein-Wide Mendelian Randomization Analysis

Cerebrospinal and Brain Proteins Implicated in Neuropsychiatric and Risk Factor Traits: Evidence from Mendelian Randomization

Protein Identification for Stroke Progression via Mendelian Randomization in Million Veteran Program and UK Biobank

Influence of Genetic Variation on Plasma Protein Levels in Older Adults Using a Multi-Analyte Panel

Phenome-wide Mendelian randomization mapping the influence of the plasma proteome on complex diseases

Identification of novel drug targets for Alzheimer’s disease by integrating genetics and proteomes from brain and blood